Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
Gyre Therapeutics (GYRE) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Gyre Therapeutics's actual EPS was -$0.00, missing the estimate of $0.04 per share, resulting in a -3647.83% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
